<DOC>
	<DOC>NCT00321815</DOC>
	<brief_summary>To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.</brief_summary>
	<brief_title>Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Advanced, EGFRpositive NSCLC ECOG Performance Status 0, 1 or 2 Measurable disease Known CNS metastasis Preexisting autoimmune or antibody mediated disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>advanced carcinoma non-small cell lung EGFR positive Erlotinib Tarceva PF-3512676 Phase II immunotherapy immune modulator</keyword>
</DOC>